Agile Therapeutics Inc., a company dedicated to women's healthcare, is making significant strides in the world of prescription contraceptive products. The New Jersey-based company is researching, developing, and commercializing these products specifically for women living in the United States. Their pioneering product, Twirla, also known as AG200-15, is a revolutionary once-weekly prescription combination hormonal contraceptive patch. Agile Therapeutics is also currently hard at work developing a pipeline of Twirla line extensions and other exciting products, such as the AG200-15 Extended Regimen (ER), which permits women to have four episodes of withdrawal bleeding per year; the AG200-15 smaller patch (SmP), which provides shorter and lighter withdrawal bleeds and enhances contraceptive efficacy; AG200-15 ER SmP, which provides an opportunity for women to extend the length of their contraceptive cycle while also experiencing shorter and lighter withdrawal bleeding episodes per year; and the P-Patch, a progestin-only contraceptive patch intended for women who are either unable or unwilling to take estrogen. Agile Therapeutics was founded in 1997 and has since become a leading authority in women's healthcare, with its headquarters based out of Princeton, New Jersey.